Global Oliguria Market, By Drugs (Furosemide, Mannitol, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Oliguria Market Analysis and Size
The global oliguria market is expected to witness significant growth during the forecast period. The factors that boosted the growth of the oliguria market are increased cases of oliguria diseases and fluid retention problems across the world. The vulnerable aging population would influence the demand for oliguria treatment. It is assumed that market for oliguria is primarily hampered by certain adverse effect coupled with product discontinuation. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global oliguria market in the forecast period 2022-2029. The expected CAGR of global oliguria market is tend to be around 5.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Oliguria, also known as hypouresis or oligouresis is defined as a condition of low urine output that is less than 400 mL or 500 mL per day in adults. It is primarily caused by dehydration, infections or trauma. In this condition, patient experienced dry skin, rapid heartbeat and enlarged kidneys.
Oliguria Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Furosemide, Mannitol, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India)
|
|
Market Opportunities
|
|
Global Oliguria Market Dynamics
Drivers
- Prevalence of Oliguria
The occurrence rates of oliguria varies for every age group. In adults, the occurrence is about 1% at admission, 2-5% during hospitalization, and 4-15% after cardiopulmonary bypass. Oliguric acute kidney injury occurs in about 10% of newborn intensive care unit (ICU) patients. Thus this rate boosts the growth of the market.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of rhinitis therapeutics delivered through retail pharmacies and the increase in the number of these pharmacies in developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Growing Elderly Population
Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies. Thus, this set of population demands high use of oliguria therapeutics and in return creates more opportunities for the market growth.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified healthcare professionals who are unable to treat these patients with appropriate treatments could curb the growth of the global oliguria market over a forecast period.
- High Cost
The huge expenditure associated with the treatment of oliguria hamper the market growth because of its expensive drugs.
This global oliguria market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global oliguria market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Oliguria Market Scope
The global oliguria market is segmented on the basis of drugs, route of administration , distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Furosemide
- Mannitol
- Others
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Oliguria Market Regional Analysis/Insights
The global oliguria market is analysed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global oliguria market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global oliguria market throughout the forecasted period due to the increase prevalence of fluid retention problem and advanced healthcare facilities.
North America dominates the market due to the increase government initiatives and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Oliguria Market Share Analysis
The global oliguria market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global oliguria market.
Key players operating in the global oliguria market include:
- Pfizer Inc.(U.S.)
- Merck KGaA (Germany)
- Sanofi (France)
- Biocare Medical, LLC (U.S.)
- Lilly (U.S.)
- Teva Pharmaceutical Industries (Israel)
- Mitsubishi Chemical Group Corporation (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Cipla Inc. (India)
SKU-